Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through Treatment of Prediabetic Individuals by Nigetella Salivata or Metformin

What this Trial Is About

Researchers are studying how two proteins, p53 and SIRT1, may affect the development of type 2 diabetes. The study focuses on people who have prediabetes and aims to understand the impact of treatments with either Nigetella salivata, a natural substance, or the medication Metformin. This is a Phase 3 clinical trial exploring these options to see their effects on insulin resistance. Participants will be randomly assigned to one of three groups: lifestyle control only, Metformin taken 500 mg twice daily, or Nigetella salivata taken 450 mg twice daily. The treatments will be given over a period of time to compare how each affects insulin resistance in people with prediabetes. No blinding is involved, meaning both researchers and participants know which treatment is given. During the study, participants will be monitored to measure changes in insulin resistance over six months. Researchers will assess who shows improvement in insulin resistance, which is a key factor in diabetes development. Participants will follow their assigned treatments and lifestyle guidance while being regularly evaluated to track progress and study outcomes.

Impact of P53 and SIRT1 in Type 2 Diabetes